Last reviewed · How we verify
Fluvoxamine+sugar pill
Fluvoxamine selectively inhibits serotonin reuptake at the presynaptic neuron, increasing synaptic serotonin availability.
Fluvoxamine selectively inhibits serotonin reuptake at the presynaptic neuron, increasing synaptic serotonin availability. Used for Obsessive-compulsive disorder, Major depressive disorder, Social anxiety disorder.
At a glance
| Generic name | Fluvoxamine+sugar pill |
|---|---|
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT), preventing reuptake of serotonin from the synaptic cleft back into the presynaptic terminal. This increases serotonin concentration in the synapse, enhancing serotonergic neurotransmission. The sugar pill component is pharmacologically inert and serves as a placebo control in this formulation.
Approved indications
- Obsessive-compulsive disorder
- Major depressive disorder
- Social anxiety disorder
- Panic disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Asthenia/fatigue
- Sexual dysfunction
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluvoxamine+sugar pill CI brief — competitive landscape report
- Fluvoxamine+sugar pill updates RSS · CI watch RSS
- Guangdong Provincial People's Hospital portfolio CI